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ABSTRACT
Introduction: Nail psoriasis is relatively
difficult to treat. Excimer laser has been
approved for the treatment of psoriasis since
2000. Pulsed dye laser (PDL) in psoriasis therapy
has shown good response rates, with extended
remissions. This is the first study assessing both
the excimer and PDL lasers in nail psoriasis.
Methods: In a comparison study, excimer laser
versus PDL for the treatment of nail psoriasis
was evaluated in 42 patients. The right hand
nails were treated with excimer laser twice
weekly and the left hand nails were treated
with PDL once every 4 weeks, for total 12 weeks.
The patients were then followed up after a
further 12 weeks. Nail Psoriasis Severity Index
(NAPSI) scores were recorded at baseline, weeks
4, 8, and 12, and then at week 24. Patients were
also asked to grade the clinical response to each
treatment.
Results: A total of 304 nail changes, 148 with
excimer laser and 156 with PDL, were treated.
The mean NAPSI score in nails treated with
excimer laser was 29.8 at baseline, reduced to
16.3 at week 24. In PDL-treated nails, the
NAPSI scores dropped from 29.5 at baseline to
3.2 at week 24. NAPSI improvement was
significantly greater in PDL than excimer
(P = 0.001; Wilcoxon signed-rank test).
Thirty-four (81%) hands achieved NAPSI-50,
and 23 (55%) achieved NAPSI-75 at week 12,
while complete nail recovery was shown in 6
(14%) hands treated with PDL. Regarding the
hands treated with excimer laser, only 16
(38%) hands achieved NAPSI-50, while no
hands achieved NAPSI-75 at week 12. In
general, subungual hyperkeratosis and
onycholysis improved significantly, while nail
pitting was least responsive. Oil drops and
splinter hemorrhages showed moderate
response.
Conclusions: When compared to excimer laser,
PDL demonstrated a good response for treating
nail psoriasis, with minimal side effects.
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INTRODUCTION
Psoriasis is a common inflammatory
proliferative disease of the skin which affects
1–3% of the world’s population [1]. Nail
involvement has long been recognized as a
common manifestation of psoriasis. Nail
abnormalities are evident in up to 50% of
patients with skin psoriasis and may be the
first manifestation of the disease [2]. The
lifetime incidence of nail involvement in
psoriatic patients is approximated to be
between 80% and 90% [3]. The disease can be
limited to the nails, by affecting a few or several
nails.
Nail psoriasis is usually challenging to treat
which may be due to the difficulty of topical
treatments to penetrate through the nail plate,
and the long-term treatment necessary for
obtaining any clinical benefit due to the slow
growth rate of the nail plate [2]. As proposed by
Rich and Scher [4], the Nail Psoriasis Severity
Index (NAPSI) has been considered an objective
and reproducible tool for assessing nail
involvement in psoriatic patients, and can
therefore be used to test the effectiveness of
therapeutic interventions.
Lasers have been shown to be effective in the
treatment of psoriasis vulgaris, but the
information for their effectiveness in nails is
limited and has just started to emerge. The use
of excimer laser for the treatment of psoriasis
was first documented in 1997, when it was
compared with full body treatments of
narrowband ultraviolet (UV) B [5]. The
possible explanations for the superior efficacy
of the excimer laser over traditional UVB
therapy for psoriasis may be due to a higher
intensity UV light to plaques, which is more
effective in clearing psoriasis [6]. The excimer
laser induces T-cell apoptosis characterized by
breaks in DNA strands as well as expression of
mitochondrial proteins associated with cell
death [7].
The pulsed dye laser (PDL), which uses a
liquid dye medium rather than a gas medium
used by the excimer laser, was first suggested as
a treatment for psoriasis in 1992 [8].
The assumption that selective laser ablation
of dermal papillary vasculature may lead to
resolution of plaque psoriasis is supported by
immunohistochemical studies, endorsing
changes in the superficial capillary bed in
psoriatic lesions, with reduction in the
endothelial surface area and proliferation,
supplemented by reduction in T-lymphocyte
infiltrate [9, 10].
Traditional treatments for nail psoriasis,
which include topical or intralesional
corticosteroids, topical vitamin D3 analogs,
photochemotherapy, oral retinoids,
methotrexate, and cyclosporin, can be time
consuming, painful, or limited by significant
toxicities [11]. Treatment of nail psoriasis is
disappointing, and a study has shown that only
19.3% of patients presented with noticeable
improvement during any topical treatment
[12].
Fingernail disease is noticeable during the
entire year and has a negative influence on
social, emotional, and business interactions and
over 50% of patients report concomitant pain
leading to limitations of daily activities [13].
The aim of this study was to evaluate and
compare the effect of PDL versus excimer laser
as treatment modalities for nail psoriasis.
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METHODS
Patients with clinically significant nail changes
were selected from psoriasis patients attending
the dermatology outpatient clinics in Farwaniya
Hospital (Kuwait) after approval from the
hospital ethics committee and informed
consent signed by each patient. The inclusion
criteria were: patients at least 16 years old and
psoriatic nail disease refractory to other topical
and systemic therapy. Among the individual
nail changes looked for were nail pits,
discoloration, thickening, onycholysis,
longitudinal ridging, subungual
hyperkeratosis, splinter hemorrhages, oil drop,
and salmon patch. Exclusion criteria were:
pregnancy, history of photosensitivity or
keloid formation, patient with severe wound
around finger nails or paronychia, and systemic
therapy for psoriasis within past 6 months.
Potassium hydroxide smears were examined in
all nails where a possibility of fungal infection
was considered. If positive for dermatophytes,
these patients were excluded from the study.
For each subject, a detailed proforma was
completed in which data regarding disease
history along with a detailed clinical
examination of the nails was recorded.
Severity of nail disease was scored at baseline
by NAPSI.
It was decided to treat the left hand finger
nails with PDL (595 nm, V beam; Candela Laser
Corporation, Wayland, MA, USA). The pulsed
duration used was 1.5 ms, the beam diameter
was 7 mm, and the laser energy was from 8.0 to
10.0 J/cm2, with 30 ms cryogen spurt and 30 ms
delay. Treatment was done once every month
until nail clearance or for a maximum of
3 months. The right hand finger nails were
treated with XeCl2 excimer laser (TALOS;
Wave Light Laser Technologie G, Erlangen,
Germany). Minimal erythema dose (MED) was
calculated on unaffected skin, and treatment
was commenced at twice the MED. The fluence
was increased by 200 mJ at each session, until
nail clearance had been achieved or for a
maximum of 12 weeks (24 treatments). The
highest fluence used was 5,000 mJ/cm2. The
patients were reassessed every 4 weeks during
the laser treatment, and then 12 weeks after the
last laser session, for clinical signs namely
pitting, onycholysis, and leukonychia, and for
the extent and severity of nail psoriasis on the
target fingernail, by means of the NAPSI score.
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Fig. 1 Serial NAPSI scores in both treatment groups.
a Comparison of total nail mean Nail Psoriasis Severity
Index (NAPSI) score in PDL and excimer laser groups.
b Comparison of nail bed mean NAPSI score in PDL and
excimer laser groups. c Comparison of nail matrix mean
NAPSI score in PDL and excimer groups
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The Statistical Package for the Social Sciences
(SPSS for Windows, Rel. 11.0.1; IBM
Corporation, Armonk, NY, USA) was used for
the statistical analysis. Analysis of variance for
repeated measures and the Friedman test were
used to analyze difference of NAPSI measures
during the period of treatment. The NAPSI
scores were divided into nail matrix, nail bed,
and total nail for each nail (Fig. 1).
Patients were asked to grade the clinical
response to treatment every 4 weeks during
the active treatment period, and then at
12 weeks after the last laser session on a
4-point scale as follows: 0, no change; 1,
moderately better (up to 50% overall
improvement); 2, much better (between 50%
and 75% overall improvement); or 3, cleared
(100% improvement).
RESULTS
Forty-two patients (23 female and 19 male) aged
between 16 and 70 years (mean ± SD
40.37 ± 18.36) and affected by symmetrical
nail psoriasis in two to five fingernails of both
hands (mean 2.14 ± 0.81) were enrolled. The
most common nail change seen in our study
was nail pitting (71.1%) followed by
onycholysis (48.7%; Table 1). A total of 304
nail changes, 148 with excimer laser and 156
with PDL, were treated.
The mean NAPSI scores in nails treated with
the excimer laser were 29.8 at baseline, reduced
to 11.8 at the third month, and 16.3 at the end
of 12 weeks of follow-up after stopping the
sessions (Table 2). Statistically significant nail
improvement was noted in most patients
treated with PDL in the third month as
evident from reduction of the mean NAPSI
from 29.5 at baseline to 3.7, in week 12, and
3.2 at the end of 12 weeks of follow-up
(P\0.001; Friedman test).
There was no statistically significant
difference in NAPSI scores at baseline, but after
3 months treatment period, there were
statistically significant difference between the
results of excimer laser treatment and PDL,
evident by mean NAPSI reduction. The serial
NAPSI scores for the two treatment groups at
baseline, weeks 4, 8, and 12, and finally at week
Table 1 Percentage of nail changes seen in study patients
at base line














Oil drop discoloration 5.6 5.4
Splinter hemorrhages 1.7 1.6
Salmon patch 1.6 1.6
Table 2 Change in nail psoriasis severity index (NAPSI)
during the period of treatment, and at the end of follow-up
(week 24)







0 (baseline) 29.5 18.5 29.8 17.9
4 21.3 13.7 26.4 23.7
8 12.4 21.4 21.2 38.5
12 3.7 17.3 11.8 22.6
24 3.2 18.6 16.3 10.3
PDL pulsed dye laser, SD standard deviation
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24 follow-up for the whole nail, nail matrix, and
nail bed are shown in Fig. 1.
The baseline mean NAPSI score was not
significantly different between the PDL and
excimer groups (Fig. 1a). The mean decrease in
nail bed NAPSI score from baseline to 6 months
was significantly greater in the PDL group than
in the excimer group (Fig. 1b). The mean
decrease in nail matrix NAPSI score from
baseline to 6 months was also statistically
significant between both the PDL and excimer
group (Fig. 1c). The overall evaluation
concerning PDL and excimer laser according
to difference between the baseline mean NAPSI
score and 6 months NAPSI score was statistically
significantly different (P = 0.001; Wilcoxon
signed-rank test).
Thirty-four (81%) hands achieved NAPSI-50,
and 23 (55%) achieved NAPSI-75 at week 12,
while complete nail recovery (Fig. 2) was shown
in 6 (14%) hands treated with PDL. Regarding
the hands treated with excimer laser, only 16
(38%) hands achieved NAPSI-50, while no hand
achieved NAPSI-75 at week 12.
Regarding the morphology of nail lesions,
the most significant improvement was noticed
in subungual hyperkeratosis and onycholysis
while the least responsive nail change was nail
pitting. Oil drops and splinter hemorrhages
showed moderate response.
Patient self-evaluation of the clinical
response to each treatment at the end of
treatment is shown in Table 3. Twenty-five
patients in the excimer laser side stated that
they did not notice any change, while no one
noticed complete clearance. All patients stated
that they had improvement in the PDL-treated
nail side, with six patients noticing complete
cure of their nail psoriasis.
Adverse reactions to excimer laser included
slight pigmentation of the treated nail folds in
five and a deep brown-black discoloration of the
treated nails in one patient. Adverse reactions to
PDL were mild including hyperpigmentation in
one patient transient and petechiae in two
patients.
DISCUSSION
To date, there are no studies that compare the
efficacy of excimer laser with PDL for the
treatment of nail psoriasis. Psoriasis of the
nails persists as a problem in patients treated
with laser therapy due to the lack of penetration
of photons through the nail plate.
The 308-nm excimer laser was approved by
the US Food and Drug Administration in 2000
for the treatment of psoriasis. It has now
become a well-known treatment modality for
Fig. 2 Effect of pulsed dye laser (PDL) therapy on nail in
one of the patient showing almost complete clearance.
a Before PDL treatment. b After PDL treatment (week 12)
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mild-to-moderate localized psoriasis. Since it is
a high-energy monochromatic UVB supplied at
308 nm that makes it possible to practically
treat individual areas of psoriasis in short period
of time. In contrast to traditional phototherapy
techniques, this handheld device selectively
targets lesional skin, thus sparing the
surrounding normal skin from unnecessary
radiation exposure. It has been shown to be
effective in the treatment of different types of
psoriasis, such as plaque psoriasis [14, 15],
palmoplantar psoriasis [15–18], scalp psoriasis
[15, 17, 19], and inverse psoriasis [20]. The
excimer laser appears to exert its therapeutic
effect by direct T-cell cytotoxicity. It induces
T-cell apoptosis, inhibits cytokine secretion,
and impairs antigen presentation by
Langerhans cells [16]. However, so far excimer
laser has not been found to be effective in
limited number of patients of nail psoriasis
available in the literature [21]. This could be
because of the poor penetration of UVB in the
human nail plate [22]. PDL treatment might be
considered for the treatment of localized,
recalcitrant plaque psoriasis, when other
topical therapies have failed [23, 24]. PDL
treatment decreases the number of dermal
papillary microvessels, which are important
pathogenetic targets of psoriasis; PDL therapy,
as it selectively targets superficial vessels, is
therefore a valid therapeutic approach [25].
In a controlled comparative study of excimer
laser and PDL in the treatment of psoriasis,
Taibjee et al. [26] found that both treatments
were useful, but the excimer laser was deemed
more efficacious than the standard treatment
regimen of PDL in the treatment of psoriasis
[15].
In this study, we used the right and left hand
of each selected patient to create a comparative
study about the effect of therapy with PDL and
excimer laser in the same patient. According to
our results, the PDL was shown to be more
effective and less time consuming in the
treatment of nail psoriasis than the excimer
laser.
In the current study, only 16 (38%) hands
treated with excimer laser showed moderate
improvement, and no hand showed complete
clearance (according to the patients overall
assessment of the results). A pilot study by
Aubin et al. [21] for evaluation of the 308-nm
monochromatic excimer light delivery system
in different chronic localized dermatoses found
that four patients with nail psoriasis
demonstrated no benefit from this type of
treatment.
In contrast, according to the current results,
PDL was shown to be a good alternative
treatment for nail psoriasis. A marked decrease
in NAPSI score was observed with PDL
treatments in both nail matrix and nail bed
involvement. Thirty-four hands achieved
NAPSI-50, and 23 achieved NAPSI-75 at week
12, while complete nail recovery was shown in
6 hands treated with PDL. The results obtained
Table 3 Patient evaluation of the clinical response to each treatment at the end of treatment period (week 12)
Laser No change Moderately better Much better Cleared P value*
Excimer 25 (59.5) 13 (31.0) 4 (9.5) 0 (0.0) \0.001
PDL 0 (0.0) 17 (40.5) 19 (45.2) 6 (14.3)
Values are given as n (%)
PDL pulsed dye laser
* Paired Wilcoxon signed-rank two-tailed test
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were well maintained throughout the follow-up
period of 12 weeks, and NAPSI-50 and NAPSI-75
scores were similar even at the end of week 24.
The personal impression of the patients was
good regarding PDL treatment.
Several reports have been published recently
about the effect of PDL in the treatment of nail
psoriasis. In 2009, Ferna´ndez-Guarino et al.
[27] evaluated the efficacy of PDL versus
photodynamic therapy in the treatment of
refractory nail psoriasis in a left-to-right
comparative pilot study of 14 patients. Both
hands were treated with 595-nm PDL (7 mm,
6 ms, 9 J/cm2), following 3 h occlusion of
methyl-aminolaevulinic acid (MAL) to 1
hand, once a month for 6 months. They
showed that both treatments were equally
effective in nail bed and nail matrix lesions,
and that MAL did not play any role in the
treatment of nail psoriasis. In 2010, Oram et al.
[28] treated nail psoriasis of 5 patients by
595-nm PDL once monthly for 3 months, with
significant improvement, particularly of nail
bed lesions. Mean NAPSI score dropped from
21.2 at baseline to 3 after 3 months [28]. In
2012, Treewittayapoom et al. [29] evaluated
the effect of two different pulse durations
(6 ms, 9 J/cm2 vs. 0.45 ms, 6 J/cm2 both with
7 mm spot size) of PDL in a left-to-right
comparison study of 20 patients. There was
no significant difference between the longer
and the shorter pulse duration groups. PDL was
found to be effective in both nail bed and
matrix lesions. A significant reduction in
NAPSI scores was observed in both groups
after 6 months of the first treatment [29].
Another study evaluating the effect of
different pulse durations in the treatment of
nail psoriasis with the 595-nm PDL to
determine the optimal pulse duration was
reported by Goldust and Raghifar [30]. PDL
was applied on the proximal and lateral nail
folds based on random assignment for forty
patients with bilateral fingernail psoriasis.
Eighty nails were treated with 6-ms pulse
duration and 9 J/cm2 whereas 80 nails were
treated with 0.45-ms pulse duration and 6 J/
cm2. After 6 months of first treatment, there
was a significant reduction in overall NAPSI,
nail matrix NAPSI, and nail bed NAPSI scores
from baseline in both groups; with no
significant difference between the two pulse
duration groups [30].
A single-blind, intrapatient left-to-right
controlled study about the efficacy of PDL plus
topical tazarotene versus topical tazarotene
alone in psoriatic nail disease was reported by
Huang et al. [31]. They included two groups of
patients: (1) patients with severe psoriasis who
were receiving stable systemic therapy
(phototherapy and systemic medication); (2)
patients with mild psoriasis who were not
receiving systemic therapy. One hand received
the experimental treatment (PDL and
tazarotene 0.1% cream) and the other, the
control treatment (tazarotene 0.1% cream). All
five fingernails of the experimental hand were
treated with 595-nm PDL once a month for
6 months. The mean decrease in modified
NAPSI score from baseline to 6 months was
significantly more after the experimental
treatment than the control treatment. They
concluded that PDL plus topical tazarotene
0.1% cream is an effective and safe therapy in
the treatment of nail psoriasis [31].
Limitations
The study should have been for 6 months of
active treatment and then a follow-up for
same duration, but because of pressing reasons
the authors could not do it. Also, a double-
blinded nature would have carried more
weightage.
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CONCLUSION
In recent years, excimer laser and PDL have
demonstrated noticeable effects for the
treatment localized plaque psoriasis. Although
the excimer laser appears to be, on average,
more efficacious than PDL for plaque psoriasis
treatment, the contrary seems to be correct for
nail psoriasis treatment. Results of the excimer
laser in nail psoriasis are poor and time
consuming. Whereas, PDL has an excellent
response for treating nail psoriasis, with
minimal side effects.
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